Ozempic Lawsuit 2026 Update | Side Effects, Claims & Legal News

The Ozempic Lawsuit focuses on allegations that the diabetes and weight loss drug Ozempic (semaglutide) has caused severe side effects such as gastroparesis, intestinal blockage, and pancreatitis. Plaintiffs claim that Novo Nordisk, the manufacturer, failed to warn patients and doctors about these potential dangers. With lawsuits increasing nationwide, courts are now reviewing the evidence and determining whether the company should be held liable. On this page, we cover everything about the Ozempic lawsuit 2026, including health risks, eligibility to file, recent legal updates, court decisions, and what to expect in the coming months.

What the Ozempic Lawsuit Is About?

The Ozempic lawsuit centers on claims that the diabetes and weight-loss drug Ozempic (semaglutide) causes severe and sometimes irreversible gastrointestinal injuries. Plaintiffs allege the drug can lead to stomach paralysis (gastroparesis), intestinal obstruction, and persistent vomiting. Many also report gallbladder and pancreatic complications.

The lawsuits argue that Novo Nordisk, Ozempic’s manufacturer, failed to provide adequate warnings about these serious risks. While the drug was marketed as safe and effective for managing blood sugar and weight loss, growing evidence suggests that long-term use may cause lasting harm to the digestive system.

As cases continue to be filed across the United States, the Ozempic lawsuit has become one of the most closely watched pharmaceutical litigations, potentially setting new standards for how side effects in weight-loss and diabetes drugs are disclosed and regulated.

Timeline of the Ozempic Lawsuit 2026

The Ozempic lawyers are dedicated to informing you about the most recent updates and news surrounding this litigation. Please make it a point to come back often. Our attorneys regularly update this page for any new developments or news.

September 17, 2025 – Streamlined Filing System Introduced in Ozempic MDL

The lawyers engaged in multidistrict litigation arising out of Ozempic have generated a joint proposal for a new Case Management Order, under which both a Master Complaint and Short Form Complaint process would be introduced, simplifying and speeding case filings so that plaintiff cases thereafter need not state again the long and complicated factual details needed for joining the MDL.

This means that lawyers would have to refile existing cases using this new format, but the revision is a minor one. As per the arrangement, defendants would get 60 days to respond to the Master Complaint, and motions to dismiss are also to follow a preset timeline. The new framework is viewed as providing a good organizational enhancement in pursuit of efficiency and uniformity of the growing pool of claims relating to Ozempic.

September 11, 2025 – Eli Lilly Pushes for Vision Loss MDL Consolidation

Eli Lilly has formally moved to consolidate all federal lawsuits alleging vision loss from GLP-1 receptor agonist medications, specifically in cases alleging non-arteritic anterior ischemic optic neuropathy (NAION). The company seeks either the establishment of a new multidistrict litigation (MDL) entitled “GLP-1 RAs Products Liability Litigation (No. II)” or for these claims to be incorporated within MDL No. 3094, which is already overseeing gastrointestinal injury lawsuits concerning drugs such as Ozempic, Wegovy, Mounjaro, and Trulicity. 

Lilly requested that all cases be assigned to Judge Karen Marston of the Eastern District of Pennsylvania, the same judge presently overseeing MDL 3094. In support of this motion, Lilly contends that her experience with the scientific and regulatory issues regarding GLP-1 drugs makes her the most qualified to aid in the rapid and efficient prosecution of this litigation.

The unusual aspect of this is that rarely do defendants ask for MDL consolidation, for fear that such a request might empower the plaintiffs and ramp up discovery loads. Lilly’s bold attempt suggests a conciliatory gesture toward the preservation of continuity before an agreeable sitting judge; the filing lists cases that combine claims of gastrointestinal injuries with those of vision loss and suggests the need for certain pretrial management coordination. Whatever the decision, the NAION-related docket in New Jersey continues to linger, with a reflection of the federal increase in these lawsuits across the nation.

September 6, 2025 – Current Categories of Ozempic-Related Lawsuits

Following Judge Marston’s latest directive, attorneys are now focusing on two primary claim types in the Ozempic and GLP-1 litigation:

1. Vision damage cases, particularly those involving NAION
2. Gastroparesis claims, verified through medical testing such as gastric emptying studies, breath tests, or wireless motility capsules.

These criteria help refine which cases qualify for inclusion under the court’s updated parameters.

September 5, 2025 – FDA Tightens Oversight on GLP-1 Raw Material Sources

The FDA has released a new “green list” of globally endorsed manufacturers approved to provide raw material for compounding GLP-1 drugs such as Wegovy and Mounjaro. It aims to curb the use of unverified or counterfeit pharmaceutical components in compounding, thus ensuring high quality and safety in constituents.

While there are said to be more than three dozen overseas suppliers on the list, their names are kept under wraps, with imports now facing detention from unapproved producers. Following the announcement, Eli Lilly and Novo Nordisk stock went down, much to the alarm of the investors who feared stricter scrutiny in the GLP-1 market.

September 1, 2025 – FDA Extends the Use of Wegovy for Fatty Liver Disease

Metabolic dysregulated steatohepatitis is MASH. It is also a progressive, serious form of fatty liver disease occurring in adults with moderate to severe fibrosis. The FDA has approved Wegovy (semaglutide) to treat MASH. This is the first-ever GLP-1 medication approved for MASH management. 

Wegovy gives new therapeutic hope to patients with liver disease, just as it has effectiveness for obesity treatment; however, the benefits must be weighed against its risks. According to the experts, that balance relies heavily on physicians having the full safety information available for the patients to make informed treatment decisions.

August 15, 2025 – Key Federal Rulings Reshape GLP-1 MDL Landscape

The U.S. District Judge Karen Spencer Marston pronounced two significant rulings directing multidistrict litigation concerning GLP-1 receptor agonists, with upwards of 2000 cases currently targeted at Novo Nordisk and Eli Lilly. 

The most recent order by Judge Marston dealt with several Daubert challenges, ruling that for any claim of gastroparesis, there must be proof by objective medical evidence, such as a gastric emptying study. It provides a stricter test for the admissibility of claims; this will, however, reduce unmeritorious claims while enhancing the credibility of the legitimate ones.

The defendants also argued for the dismissal of twelve out of seventeen counts in the master complaint, claiming their promotional statements labeling their drugs “safe and effective” amounted to non-actionable puffery and that design defect claims were preempted by federal law. The court partially agreed, dismissing design defect claims and some fraud claims that lacked clarity, but Judge Marston ruled that the puffery defense was not applicable since the specific marketing statements made some of them by paid experts and influencers went way beyond simply puffery and could mislead the consumer.

Significantly, the court ruled that the claims that Novo and Lilly should have included adjuncts about the gastroparesis risks in their labeling were sufficiently detailed to go forward. This drives a wedge against all diagnosed plaintiffs with evidence to substantiate their claims of harm while allowing the discovery to continue regarding those who know that Novo and Lilly suppressed safety data in marketing GLP-1 drugs for profit. 

While this ruling creates a vastly narrower pool of prospective litigants by excluding all without verified diagnostics, it strengthens the heart of the litigation’s case: that the companies put commercial success ahead of the welfare of their patients, thereby creating the clearest path to justice for those injured by the same.

August 14, 2025 – New Jersey Vision Loss Litigation Expands

Novo Nordisk now faces increasing legal scrutiny in New Jersey state court, where a group of plaintiffs is attempting to coordinate multicounty litigation (MCL) on claims that the drugs Ozempic and Wegovy have caused permanent vision loss. The petition has grown to include over thirty plaintiffs, up from twenty-one in mid-June, each claiming to have developed non-arteritic anterior ischemic optic neuropathy (NAION), a rare, irreversible eye disorder, as a result of taking these GLP-1 drugs. The cases, hailing from thirteen different states, are presently before eight judges in Middlesex County, which has been proposed by the plaintiffs as the central venue for coordination. 

It is most often treated as a ‘class action’ but is in fact a mass tort consolidation of many lawsuits concerning similar subject matter and injuries against one or more defendants. Under the multicounty litigation system, each plaintiff preserves his or her own case while pretrial proceedings, discovery, expert evaluation, motion practice, etc., are all performed together for all the cases. This avoids redundancy while moving the cases along faster.

In turn, this tends to strengthen plaintiffs’ bargaining power early on, during bellwether trials or settlement talks. New Jersey has become the state most frequently targeted for mass tort claims, with plaintiffs claiming that it offers fewer procedural delays and fewer burdens in terms of evidentiary hurdles as compared with federal MDLs. In short, plaintiffs’ firms see state coordination as a faster and more strategically smart alternative than going through the slow and often tedious federal process exemplified by the current Ozempic MDL.

August 1, 2025 – Rising Case Numbers in GLP-1 MDL

On 01 August 2025, there were 2,190 active cases filed under the GLP-1 Receptor Agonist MDL (No. 3072). Cases continue to be added to the docket for further claimants alleging side effects associated with the use of Ozempic, Wegovy, and Mounjaro. 

Most of these cases deal with gastroparesis, often referred to as “stomach paralysis.” While litigation interest remains constant, legal insiders say that the current atmosphere is more measured anticipation than enthusiasm. Many await the judge’s forthcoming Daubert ruling concerning scientific evidence, a discursive decision that could determine the fates of certain expert opinions. Attorneys remain cautiously optimistic, but no one is making big predictions just yet.

July 28, 2025 – Swedish Study Ties Ozempic to Eye Vessel Damage

A newly conducted observational study in Sweden has brought to light an association of potential link between semaglutide and retinal vein occlusion or RVO: a medical eye condition that could result in an abrupt loss of vision that may become permanent. 

The study found that analysis of the insurance data of over 800,000 diabetic patients revealed that patients who were using GLP-1 receptor agonists, Ozempic among others, had an increased risk of developing RVO by 1.6 times, compared to patients using other diabetes treatments. Although researchers called this an important research avenue for investigation, it does put a different spin on already high worries regarding GLP-1 and vision health.

For Novo Nordisk, the implications of this new evidence could mean tough going for the company in its legal defense against several patients who have filed lawsuits alleging NAION and other vision-related injuries caused by Ozempic and Wegovy.

July 19, 2025 – Plaintiffs Request Separate Vision Loss Track in MDL

Lawyers for the plaintiffs in Ozempic multidistrict litigation (MDL 3094) have approached Judge Pratter, seeking the establishment of a special “Vision Injury Track.” This would integrate all NAION and other ocular harm cases into a single channel for discovery, expert testimony, and bellwether selection.

At the moment, there are over 140 cases pending under this MDL, and each case will assert claims of partial blindness or complete vision loss. The observation of the plaintiffs here is that these issues are completely different and separate from those regarding any gastrointestinal injury.

There is no response from the defense yet; all this constitutes a marked shift in attention, that is, with regard to newly arising vision-related cases beginning to be a significant avenue of litigation for Ozempic, and plaintiffs’ counsel wanting to regulate how this plays out in the federal court as opposed to letting New Jersey’s state proceedings take the lead.

July 15, 2025 – Texas Lawsuit Filed Over Sudden Blindness Linked to Ozempic

A 52-year-old woman has filed a lawsuit against Novo Nordisk in Travis County, Texas, claiming that she suffered sudden and irreversible blindness after taking Ozempic for six months. According to the complaint, she has developed a non-arteritic anterior ischemic optic neuropathy (NAION) in one eye, leading to 90% irreversible damage to the eye’s vision in a single day. 

Her attorneys argue that Novo Nordisk was distanced from the early warning signs of clinical research and failed to provide adequate warnings regarding the risks to doctors and patients. This suit mentions some contemporary research indicating that semaglutide might hinder optic nerve blood flow, possibly producing an eye disease.

This lawsuit is again one of many to emerge in state courts and outside the federal MDL system. This strategy is becoming popular among plaintiffs who want faster and more visible trials in state courts. If causation can be established, it may be set up as a precedent case against the manufacturer.

June 24, 2025 – New Study Ties Ozempic and Wegovy to Broader Vision Risks

Researchers from the University of Toronto found that individuals taking semaglutide, the active agent in both drugs, had twice the odds of developing neovascular age-related macular degeneration (nAMD), a chronic affliction slowly destroying central vision. The researchers reviewed data of nearly 140,000 adults with type 2 diabetes for the period of 2020-2023 and found a statistically significant increased risk: About 2 in 1,000 users developed nAMD as opposed to 1 in 1,000 non-users, while controlling for other factors like kidney health, smoking, and other medications. The researchers pointed out the biological plausibility, indicating that GLP-1 medications affect vascular and inflammatory pathways, which are crucial for the initiation of macular degeneration. These findings have posed significant clinical questions for both physicians and patients. 

Ozempic, originally mainly marketed as a diabetes drug, became famous as a weight-loss agent long before any risk worth talking about had manifested itself in human research. Pathogenesis supporting evidence around new gastrointestinal and now possibly visual complications has further put Novo Nordisk on the spot regarding what they’ve disclosed and what they’ve failed to look into.

June 21, 2025 – New Jersey Man Files Wegovy Vision Loss Lawsuit

A New Jersey resident recently filed a lawsuit in the New Jersey Superior Court, alleging that the GLP-1 receptor agonist supplied by Novo Nordisk, Wegovy, caused him to suffer from NAION and lose his eyesight permanently. He claims that Novo Nordisk failed to provide adequate warnings to doctors and patients about the likelihood of optic nerve damage in conjunction with the side effects of Wegovy. The plaintiff seeks compensatory and punitive damages for his medical expenses, pain and suffering, and loss of enjoyment of life.

This just adds to the pile of cases that are beginning to accrue in state courts for NAION, as increasing numbers of persons report serious and enduring eye injuries believed causally linked to GLP-1 drugs.

June 17, 2025 – Push for Consolidation of NAION Vision Loss Lawsuits in New Jersey

A group of 21 New Jersey plaintiffs suing Novo Nordisk on account of being permanently blind due to the use of Ozempic or Wegovy has moved to consolidate their lawsuits into a multicounty litigation (MCL). Thus, by centralizing the suits, it is easier to determine the discovery process, enforce a consistent ruling, and maximize judicial efficiency, much like the particular federal models for gastroparesis claims.

Most significant is the shift of energy into NAION-based claims, which is now drawing even more legal interest than previous claims of gastrointestinal injury. Unlike paralysis of the stomach, vision loss has life-altering consequences and is, therefore, considered an impact claim that attracts attention from the media as well as the potential for litigation.

As research continues on the influence of GLP-1 receptor agonists on optic nerve damage, lawyers will certainly be placing more of their focus on NAION as a critical component in the growing Ozempic and Wegovy litigation landscape.

June 10, 2025 – Growing Pressure for FDA to Issue Vision Loss Warning

A growing demand is surfacing asking the FDA to take action following reported cases linking Ozempic and other semaglutide drugs like Wegovy and Rybelsus to a condition known as non-arteritic anterior ischemic optic neuropathy (NAION). Their stories have prompted calls to the agency from ophthalmologists and public health experts for a black box warning, citing an increasing body of evidence, from both JAMA Ophthalmology and Danish registry studies, finding a statistically significant association between semaglutide and sudden vision loss.

Those attorneys who are involved with the multicounty litigation in New Jersey are creeping into the chorus of voices stating that, because Novo Nordisk has been aware of these risks, they have failed to relabel their products accordingly. Thus, a black box warning would mark a shift in regulation that may redefine GLP-1 prescribing practices for doctors, in addition to bolstering the claim of plaintiffs that there was a failure to warn.

The issue is fast becoming a public health issue, moving beyond litigation. New case reports come up in the media highlighting the gravity of these injuries.

June 2, 2025 – Novo Nordisk’s Early Defense in Vision Loss Lawsuits

Novo Nordisk has signaled how to defend itself against the looming tide of NAION lawsuits: attribute vision loss to preexisting conditions like diabetes, hypertension, and high cholesterol, known as risk factors for optic nerve damage. The company argues that these injuries suffered by plaintiffs may not be related to semaglutide at all.

 NAION is thus defined as being multifactorial. This argument would be typical in defense of any pharmaceutical claim, but it also has its risks before a jury. According to plaintiffs’ arguments, Novo Nordisk should also have a duty to warn even when such a drug might, to a small extent, increase the existing threats. Emerging data of NAION cases within the relatively healthy users without prior eye problems are the primary basis of their argument.

If these cases should go to expert testimony, the juries may consider Novo Nordisk to downplay what could be viewed as catastrophic effects, setting the stage for a distinctly high-profile and separate litigation battle, apart from the gastroparesis MDL.

May 19, 2025 – Ozempic Vision Loss Lawsuits Highlight NAION Risk

The widening scope of Ozempic litigation sees several plaintiffs file lawsuits claiming to have suffered irreversible blindness following the development of NAION. These cases claim that Novo Nordisk failed to warn doctors and patients about the possibility of optic nerve damage associated with the drug, despite clinical data, post-marketing reports, and adverse event information suggesting otherwise.

Notably, the current label for Ozempic provides no warnings for vision loss or NAION; plaintiffs view this as a stark omission that proves safety took a backseat to marketing strategies. In a somewhat nefarious parallel, the more recent lawsuits also cite the company’s aggressive promotion of Ozempic for weight loss on an off-label basis, in spite of scant long-term safety data. 

Lawyers believe that the NAION cases should offer up higher settlements than other GLP-1 injury claims, since blindness is so profoundly altering to someone’s way of life. The Wegovy and Rybelsus-related lawsuits are gaining momentum as well, giving birth to a new front in the semaglutide litigation arena.

April 22, 2025 – Oral Arguments Begin in GLP-1 Litigation

Novo Nordisk and Eli Lilly, their attorneys, today in court, have filed and argued their motion to dismiss most of the claims pending. According to the companies, many allegations in the master complaint are too vague to proceed; this argument, according to the plaintiffs, is “absurd” in the face of the details in the filing on specific gastrointestinal injuries. 

According to the plaintiffs, their claims are indeed well-founded and clearly shown with evidence from misleading advertising campaigns that overstated safety and downplayed the risks of the drugs. The defense’s “kitchen sink” critique spares the point, however: broad negligence claims are necessary strategically in nationwide litigation where state laws differ. 

At the core of the dispute is whether uniform marketing omissions-failure, especially to warn about severe gastrointestinal complications, sustains theories of fraud and negligence. Most legal observers expect these plaintiffs to win on at least some claims, but the final ruling rests with a single judge.

April 21, 2025 – CDC Study Reveals Thousands of ER Visits Linked to Semaglutide

As part of a new CDC-supported study, published in the Annals of Internal Medicine, an estimated total of 25,000 ED visits between 2022 and 2023 were associated with semaglutide. Most cases occurred in 2023 and involved injections of either Ozempic or Wegovy. The top reasons were severe gastrointestinal issues and hypoglycemia, which would be serious enough to require many hospitalizations.

The pharmaceutical companies may characterize these numbers as “rare,” but the consequences are serious: almost 40 percent of hypoglycemia cases are admitted to hospitals, and almost 15 percent of gastrointestinal cases are as well. Findings of this nature are contrary to statements the companies have made about minor side effects and augment the foremost argument of plaintiffs that semaglutide’s risks were not properly disclosed to patients or doctors.

April 9, 2025 – Expert Testimony Fight Over Gastroparesis Diagnosis

Eli Lilly and Novo Nordisk are attempting to exclude expert testimony from Dr. Daniel Raines and Dr. Eliot Siegel, key witnesses for the plaintiffs connecting Ozempic and Mounjaro to gastroparesis. The defendants maintain that without a gastric emptying study, the plaintiffs cannot prove their diagnosis, contending that the symptoms alone do not constitute sound scientific evidence. 

In rebuttal, plaintiffs insist that this position completely disregards the manner in which medicine is practiced in the real world. It’s highly unlikely that many patients actually underwent formal testing because their respective doctors deemed it unnecessary after the patients’ symptoms resolved upon cessation of the drug. Excluding hundreds of perfectly valid claims due to the failure of every plaintiff to undergo a particular diagnostic procedure would be a serious affront to justice. 

If the court were to rule in favor of the defense, thereby setting a dangerous precedent, with its inappropriately high standards of proof essentially aiding in the exoneration of pharmaceutical companies, it would invert the burden of proof in drug-induced gastroparesis cases. Timelines, patterns of symptoms, and clinical judgment are far more than enough to prove causation in cases of drug-induced gastroparesis, according to the plaintiffs’ counsel.

March 17, 2025 – Eli Lilly Pushes for Stricter Diagnostic Standard

Eli Lilly made a motion where it sought a ruling from the court that would limit reliance on the diagnosis of gastroparesis only to those with objective, contemporaneous medical testing by which it can be said that the diagnosis is “reliable.” Furthermore, the company seeks to exclude testimonies given by plaintiffs’ experts who state that clinical history, symptoms, and physician judgment can suffice without formal testing to confirm the disease.

Lilly defines this in terms of science, while claimants perceive the move as an unwrapping of a tactical gatekeeping. The truth is that many gastroparesis cases go without invasive testing, particularly in those cases wherein there are extensions of symptoms after starting GLP-1 drugs and excellent improvements after stopping the medicine. Lilly insists on such unrealistic evidentiary standards to dismiss enormous amounts of authentic claims before reaching trial. 

This motion is in keeping with the continuing theme of the company that keeps narrowing the circle of potential suitors, rather than ensuring that the medical evidence is precise. Similar tactics have often been ruled out by courts, for they would know that medicine in practice does not always fit courtroom idealizations. Plaintiffs’ lawyers have been confident that the judge will see this for what it is: an attempt to rewrite medical and legal reality in an attempt to lessen liability exposure.

February 26, 2025 – Major Study Links Semaglutide to Sudden Vision Loss

The association of semaglutide with non-arteritic anterior ischemic optic neuropathy, an infrequent eye pathology with severe consequences causing loss of vision in a sudden and irreversible way, is made even stronger with the findings of a newly emerging study in the JAMA Ophthalmology. Data from more than 37 million people with type 2 diabetes were examined, over 810,000 of whom initiated semaglutide therapy, for an increased incidence of NAION, almost 14.5 cases for every 100,000 person-years compared to non-users. Although the total risk remains low, the life-changing experience is enormous.

The authors of the study recommend that physicians advise patients regarding possible ocular adverse effects when prescribing Ozempic, Wegovy, or Rybelsus. It is bright and clear: even if such incidents are rare, permanent vision loss must earn its own clear proactive warning so that patients can make informed decisions. As such, the evidence appears to support the plaintiffs’ argument that Novo Nordisk had ample evidence to alert consumers but failed to do so.

January 28, 2025 – New Thyroid Cancer Study Adds More Fuel to the Fire

The new study published in JAMA Otolaryngology–Head & Neck Surgery has added yet another set of concerns to the already chock-full litigation on Ozempic and other GLP-1 receptor agonists. The researchers analyzed data involving more than 350,000 adults with type 2 diabetes and found that there was a significantly higher risk of thyroid cancer in patients who commenced GLP-1 medications, including the likes of Ozempic and Mounjaro, during the first year of treatment compared with patients on any other diabetes drug. 

The study does not provide us with conclusive proof that these drugs cause thyroid cancer. Medical monitoring may bias some of the findings. Depending on one’s interpretation, this correlation may not bode well. For the plaintiff attorneys, this is yet another addition to an expanding list of safety issues with GLP-1 drugs. With too many such glaring red flags rising, it becomes all the more ridiculous to dismiss them as mere coincidence. Like they say: there is too much smoke for there not to be fire somewhere.

January 22, 2025 – Another Study Challenges the “Miracle Drug” Narrative

The January 2025 study, which slightly tempered the publicity surrounding Ozempic and other forms of GLP-1 receptor agonists, found that there are complications with their overall health effects beyond what marketing suggests. 

For the study, in weighing benefits such as potential reductions in dementia and heart disease risk, GLP-1 drugs came with considerable side effects, ranging from gastrointestinal ailments, kidney stones, and arthritis to fainting and pancreatitis. Some of these complications may be life-threatening, many are life-altering, and none are properly discussed in advertising for the products. 

The conclusion is not that there should be a ban or recall of Ozempic, but the expectation is that patients ought to be fully informed about the known risk. Pharma should not be cavalier in using hype to cover real human harms, wherein actual people are made to pay the price for their glib imposition of incomplete warnings.

December 20, 2024 – Saxenda Added to the GLP-1 MDL

The Judicial Panel on Multidistrict Litigation (JPML) has now incorporated into the MDL a broader scope with respect to the existing one, which includes the issues of Saxenda. This drug, like the earlier drug, is manufactured by Novo Nordisk. However, the panel has declined to entertain blood clot-related claims such as DVT or pulmonary embolism, preferring to remain on point with common factual issues at play. 

The MDL still remains centered around the reports of gastrointestinal injuries, examples are storied paralysis (gastroparesis), except those related to the incidence of obstructions within the intestines that were thrust upon the public uniformly through the different and respective GLP-1s. While closing off claims having to do with clotting, JPML leaves the litigation in different strands and, although still manageable, it could be open to possible future claims in the context of new scientific discoveries.

November 13, 2024 – New Plaintiff Files in National GLP-1 MDL

A fresh case has been filed by a Tennessee woman in the national MDL for GLP-1 receptor agonists (GRAs) in Philadelphia, claiming that Ozempic and Wegovy gave her gastroparesis, a gut-related, serious digestive disorder. 

She was put on Ozempic in 2022 for diabetes and for weight management, but quickly developed distressing nausea, vomiting, and stomach pain. A gastric emptying study in early 2023 confirmed the delay of stomach emptying, strong medical evidence of the presence of gastroparesis, and will likely prove crucial in her case. 

The lawsuit alleges that Novo Nordisk failed to warn physicians and patients of the risks associated with severe gastrointestinal problems, such as paralysis of the stomach and blockages of the intestine. The lawsuit claims the defendant knew-or should have known-about this prognosis, given prior studies and data on adverse events. They also contend that Novo Nordisk minimized these risks within their advertising while marketing Ozempic and Wegovy as safe and effective for long-term use without adequately disclosing possible serious side effects or the possibility of weight regain after cessation of use.

November 4, 2024 – Gastric Emptying Studies Take Center Stage

Proof of gastroparesis has emerged as a serious and central point of contention in the litigation surrounding Ozempic and GLP-1 in general. The judges are giving serious thought to whether or not the plaintiffs could ever sustain a finding that Ozempic caused a gastroparesis condition or even proved its presence through good medical evidence.

Gastric emptying studies have increasingly come to be regarded as highly valuable in the assessment of this issue. These studies show how quickly food empties out of the stomach after swallowing and are considered the most validated method of diagnosing gastroparesis. To attorneys, these tests may now also emerge as significant pieces of evidence in the proof of injury claims involving drugs.

As litigation progresses, it is generally expected that plaintiffs presenting objective test results would garner stronger cases. Courts might rely on this evidence to establish an actual case of drug-induced gastroparesis as opposed to unrelated gut symptoms. This highlights that scientific proofs can make claims fail or succeed in the future.

November 1, 2024 – Scheduling Order Sets Long Road Ahead

The court has issued a detailed scheduling order for the Ozempic and GLP-1 receptor agonist litigation. The deadlines extend well into 2026, showing that the process will be lengthy and complex before individual trials can begin.

Deadline	Description
July 2, 2025	Deadline for fact discovery
July 16, 2025	Plaintiffs to serve expert reports
August 13, 2025	Defendants to serve expert reports
August 22, 2025	Plaintiffs to serve rebuttal expert reports
October 10, 2025	All parties to complete expert depositions
October 27, 2025	Motions to exclude expert opinions under Rule 702 and initial briefs due
October 29, 2025	Summary judgment motions and initial briefs due
December 3, 2025	Briefs in opposition to Rule 702 motions due
December 16, 2025	Briefs in opposition to summary judgment motions due
December 17, 2025	Reply briefs in support of Rule 702 motions due
January 16, 2026	Reply briefs in support of summary judgment motions due

This schedule confirms what many plaintiffs’ attorneys have expected the Ozempic litigation will not move quickly. These dates only cover pretrial steps, meaning that trials are still far off. It signals a long and challenging road ahead for those seeking justice.

October 29, 2024 – FDA Flags Problems at Ozempic Manufacturing Plant

Novo Nordisk’s main facility for producing its drugs Ozempic and Wegovy in Kalundborg, Denmark, has been cited by the FDA due to lapses in quality control. The inspection found a lack of proper documentation by the company regarding water utilized in production, which is necessary in the prevention of microorganism growth. This plant is one of just two worldwide manufacturing facilities for semaglutide, the active ingredient in both drugs.

Prior to this, the North Carolina factory of the company had also captured FDA tags due to inadequate investigation into bacterial contamination. The issues make it sound as though Novo Nordisk is more inclined towards output and profit-making rather than a safe and quality-assured product.

Read about the Paragard IUD Lawsuit

Health Conditions & Claims Covered in the Ozempic Lawsuit 2026

The expanding Ozempic lawsuits in 2026 focus on two major health risk categories: severe gastrointestinal injuries and vision-related damage. These claims allege that the drug and other GLP-1 receptor agonists led to life-altering complications that were not adequately disclosed to users.

Gastrointestinal Injuries

Many lawsuits claim that Ozempic caused conditions like gastroparesis (a form of stomach paralysis), ileus (where the intestines stop moving), and intestinal obstructions. Plaintiffs describe symptoms that include chronic nausea, vomiting, malnutrition, and even emergency surgery or hospitalisation. Some cases say their condition worsened even after discontinuing Ozempic. 

Vision-Loss Injuries (NAION)

Another significant focus of these lawsuits is the alleged link between Ozempic and non-arteritic anterior ischaemic optic neuropathy (NAION), a rare, often permanent eye condition that can cause sudden vision loss. Users claim they were not warned about this possibility, despite emerging studies suggesting elevated risk. A

Other Injuries Under Investigation

Beyond gut and eye injuries, the litigation also includes claims of complications such as gallbladder disease, pancreatitis, kidney damage, and blood clots. These claims highlight the potential for multiple serious side effects arising from long-term or off-label use of Ozempic.

Read about the Depo-Provera Brain Tumor Lawsuit

Who Can Join the Ozempic Lawsuit and How to File?

If you have used Ozempic and later developed a serious health condition, you may qualify to join the Ozempic lawsuit in 2026. Typically, eligible individuals must show they were prescribed Ozempic (or a similar GLP-1 drug) and later diagnosed with a significant injury such as gastroparesis, bowel obstruction, or vision loss. Critical evidence includes medical records confirming your drug use, diagnosis, and treatment.

To begin the claim process, speak with a qualified attorney who handles pharmaceutical injury cases. They will guide you through eligibility verification, documentation gathering, and filing your lawsuit before any statute of limitations expires.

Settlement Status and Compensation Outlook in the Ozempic Lawsuit 2026

As for 2026, the Ozempic litigation is in its early stages. Hundreds of lawsuits have now been consolidated into multidistrict litigation (MDL), but no global settlement has yet been reached. With more reports of people suffering from severe gastrointestinal and vision-related side effects that they claim are due to the use of Ozempic and other GLP-1 receptor agonists such as Wegovy and Mounjaro, the number of new filings is on the rise. 

First bellwether or test trials are set for 2026, and their results will likely direct the negotiations for any settlement thereafter. Trial results in these early proceedings allow both sides to assess how juries respond to material scientific evidence linking Ozempic with gastroparesis, intestinal blockage, and non-arteritic anterior ischemic optic neuropathy (NAION). A convincing verdict for the plaintiffs could catalyze making deals for a global settlement.

While it is highly premature to stipulate, analysts opine that settlement amounts could reach an extensive range, depending on the depth of injuries, however. Permanent or long-term injuries like severe gastroparesis or vision loss might warrant settlements in the range of $400,000 to $700,000 or higher. In less serious cases, awards may be considerably lower, especially if recovery was incomplete or of limited duration.

Several factors will determine each claimant’s compensation, including:

• The type and severity of the injury suffered
• The length and dosage of Ozempic use
• Medical evidence showing causation
• The strength of the expert testimony presented
• Any long-term disability, pain, or economic loss

Plaintiffs with strong medical documentation and clear links between their health condition and Ozempic use will be better positioned for higher settlements once the litigation progresses.

For now, the Ozempic lawsuit remains in its discovery and procedural phases, with many law firms still accepting new clients. Those considering a claim should preserve all medical and pharmacy records and consult a qualified attorney experienced in pharmaceutical litigation to ensure their case is filed within the applicable statute of limitations.

Also Read: Can You Sue Someone for Emotional Distress?

Legal Strategies, Court Decisions & What They Mean for the Ozempic Lawsuit

The Ozempic lawsuit has rapidly evolved into one of the most closely watched pharmaceutical mass torts in recent years. As thousands of plaintiffs file claims alleging that Ozempic and similar GLP-1 drugs caused serious injuries such as gastroparesis, intestinal obstruction, and vision loss (NAION), both sides have begun to shape their legal strategies for what could become a major multidistrict litigation battle.

Plaintiff Legal Strategies

Plaintiffs’ attorneys are focusing heavily on failure-to-warn and design defect claims. They argue that Novo Nordisk and other manufacturers failed to provide adequate warnings about the risks of prolonged gastrointestinal paralysis and other complications. Lawyers are using internal company documents, adverse event reports, and emerging medical studies to demonstrate that the drugmakers knew or should have known about these potential dangers long before widespread public awareness.

Another key tactic involves expert testimony. Plaintiff experts are expected to testify about the mechanism of GLP-1 drugs, explaining how delayed gastric emptying caused by semaglutide (the active ingredient in Ozempic) can lead to chronic and severe conditions like gastroparesis. Establishing this link scientifically will be crucial for plaintiffs to overcome defense challenges and prove causation.

Defense Legal Strategies

Defense teams for Novo Nordisk and Eli Lilly are expected to argue that there is no definitive scientific proof linking Ozempic directly to permanent stomach paralysis or vision loss. They emphasize that gastrointestinal symptoms are disclosed side effects and that most patients tolerate the medication well. In addition, they may argue that lifestyle or pre-existing conditions, such as diabetes or obesity, contribute more to these complications than the medication itself.

The defense is also working to exclude certain expert witnesses through Daubert motions, aiming to prevent testimony that they claim lacks reliable scientific backing. This mirrors strategies seen in other pharmaceutical litigations, such as the Zantac and Roundup cases, where expert admissibility often became a deciding factor in early rulings.

Key Court Developments

In early 2025, federal judges began consolidating Ozempic, Wegovy, and Mounjaro lawsuits into an MDL (multidistrict litigation) to streamline pretrial proceedings. This move allows coordinated discovery and rulings on critical motions, including expert witness admissibility and preemption defenses.

Some early procedural rulings have already favored plaintiffs by rejecting motions to dismiss and allowing discovery to move forward. However, courts have also signaled that causation evidence must meet high scientific standards similar to those applied in other drug mass torts.

What These Decisions Mean Going Forward

The outcomes of these early legal battles will set the tone for the Ozempic lawsuit in 2026. If plaintiffs succeed in getting their experts admitted and establishing a credible link between Ozempic and the alleged injuries, it could open the door to significant settlements or jury awards. Conversely, if judges rule that the scientific evidence is too speculative, it could narrow the scope of claims or delay resolution.

Overall, both sides are preparing for a long, complex fight, one that will likely hinge on evolving science and judicial interpretation. For plaintiffs, the goal is to build consistent, data-backed narratives showing corporate negligence; for the defense, the strategy is to maintain doubt and demand the highest proof threshold possible.

Read about the Gardasil Lawsuit Updates

What Comes Next in the Ozempic Lawsuit 2026?

As the Ozempic lawsuit moves forward, the litigation is entering a critical phase where early court rulings, expert evaluations, and settlement negotiations will begin to shape the direction of thousands of pending claims. With federal consolidation now underway, both sides are preparing for extensive discovery and pivotal hearings that could define the next steps in this high-profile pharmaceutical battle.

Upcoming MDL Proceedings

The newly formed Ozempic multidistrict litigation (MDL) will oversee pretrial proceedings for lawsuits involving Ozempic, Wegovy, and related GLP-1 agonist drugs like Mounjaro. Throughout 2025, judges are expected to:

• Finalize leadership appointments for plaintiffs’ counsel.
• Establish protocols for sharing corporate documents, clinical data, and expert testimony.
• Schedule the first round of Daubert hearings to determine which scientific experts can testify about causation.

These hearings are crucial because the admissibility of expert testimony will directly influence whether the cases proceed to trial or face early dismissal.

Bellwether Trials Expected in 2026

Following discovery, the court is likely to select a handful of bellwether cases for early trial dates, potentially in late 2025 or early 2026. These test trials will help gauge how juries respond to the evidence linking Ozempic to conditions such as gastroparesis, intestinal blockage, and NAION (optic nerve damage).

If plaintiffs secure favorable verdicts, it could prompt settlement discussions similar to what occurred in the Zantac, Roundup, and 3M earplug litigations. However, if early verdicts favor the defense, it could lead to prolonged negotiations or even significant claim reductions.

Ongoing Settlement Talks

Although no global settlement has been announced, informal negotiations are already underway between plaintiffs’ attorneys and drug manufacturers. Many legal analysts believe that once scientific evidence from the first wave of discovery becomes public, companies like Novo Nordisk and Eli Lilly may consider partial or tiered settlement structures based on injury severity.

Plaintiffs with severe and well-documented cases, particularly those suffering from chronic gastroparesis or vision loss, are expected to have the strongest claims and could receive higher payouts once settlement frameworks are established.

Evolving Scientific Evidence

New medical studies are expected to play a major role in the Ozempic lawsuit in 2026. Ongoing research into GLP-1 drugs and gastrointestinal motility may provide stronger evidence linking long-term semaglutide use to irreversible digestive disorders. Conversely, manufacturers are funding counter-studies to emphasize the drugs’ overall safety and effectiveness for diabetes and weight management.

Read about Simply Orange PFAS Lawsuit

FAQs on the Ozempic Lawsuit 2026